‘Game-changer’ drug will not be available on NHS
Intended for healthcare professionals
News Previous     Next

‘Game-changer’ drug will not be available on NHS

The Institute of Cancer Research (ICR) has expressed disappointment that the prostate cancer drug abiraterone will not be made available to men with advanced prostate cancer as a first-line treatment on the NHS.

Cancer Nursing Practice. 17, 4, 7-7. doi: 10.7748/cnp.17.4.7.s4

Want to read more?

RCNi-Plus
Already have access? Log in

or

3-month trial offer for £5.25/month

Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
  • Unlimited access to all 10 RCNi Journals
  • RCNi Learning featuring over 175 modules to easily earn CPD time
  • NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
  • Personalised newsletters tailored to your interests
  • A customisable dashboard with over 200 topics
Subscribe

Alternatively, you can purchase access to this article for the next seven days. Buy now


Are you a student? Our student subscription has content especially for you.
Find out more